Pediatric Tularemia 

  • Author: Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM; Chief Editor: Russell W Steele, MD   more...
 
Updated: Jul 23, 2010
 

Background

A deadly, and long-lasting epidemic (35-40 years), known as the Hittite Plague, traced back to a focus in Canaan along the Arwad-Euphrates trading route, plagued the Eastern Mediterranean in the 14th century BC. Described in Egyptian royal archives, patient symptoms, mode of infection, and geographical focus historically point to the agent as Francisella tularensis. Egypt and Anatolia were spared due to quarantine and political boundaries. Subsequently, wars spread the disease to central Anatolia, from where it was spread to Western Anatolia by the deliberate use of contaminated animals in what is hypothesized to be the first documented incident of biological warfare.[1]

In more modern times, hare-associated disease compatible with tularemia had been described in Japan as early as 1818, and Homma-Soken provided the first written description of tularemia in 1837 as a febrile illness with generalized lymphadenopathy among people who had eaten infected rabbit meat. McCoy first isolated the causative organism in 1911, following an outbreak of a plaguelike disease among ground squirrels in the extensive reed marshes of Tulare County, California.[2] In 1912, McCoy and Chapin cultured the organism, which they named Bacterium tularense.[3]

The first bacteriologically confirmed case of tularemia was an ocular infection reported by Vail in 1914. Wherry and Lamb demonstrated the organism in wild rabbits living near the home of a patient with culture-proven tularemia conjunctivitis.[4] The genus was renamed Francisella in honor of Edward Francis, whose extensive investigation of tularemia expanded the bacteriologic, syndromic, and epidemiologic understanding of the disease.[5]

Francisella tularensis is one of the most infectious bacteria known, as it can cause illness in humans with exposure to as few as 10-50 organisms. F tularensis is considered a category A biowarfare agent due to its high infectivity, ease of dissemination, and ability to cause substantial illness and death.[6, 7]

Investigation of F tularensis and its use as a biologic weapon began in World War II during the Japanese occupation of Manchuria. F tularensis was weaponized and stockpiled by the United States until President Nixon terminated the program and stores maintained by the United States military were destroyed. According to former Director of the Soviet Bioweapons program, Dr Ken Alibek, the former Soviet Union produced and maintained strains that were resistant to antibiotics and vaccines.[7] Due to US concerns regarding its potential use as a biowarfare agent, tularemia was reinstated on the list of reportable diseases in 2000.

Tularemia was quite common in the United States before World War II. Since the 1950s, the incidence had been steadily declining and had remained at fewer than 0.15 cases per 100,000 population since 1965.[8] Due to this declining incidence, tularemia had been removed from the reportable disease list in 1995, although outbreaks and sporadic cases continued to occur worldwide.[9, 10]

The World Health Organization (WHO) conducted modeling studies in 1970 on the possible use of F tularensis as an aerosolized bioweapon. The WHO estimated that an aerosol dispersal of 50 kg of virulent F tularensis over a metropolitan area with 5 million inhabitants would result in 250,000 incapacitating casualties, including 19,000 fatalities. This dispersal would also result in relapses occurring for many months after the initial exposure and the potential to establish enzootic reservoirs of tularemia in wild animals leading to possible subsequent outbreaks.

Next

Pathophysiology

F tularensis is a facultative intracellular, aerobic, gram-negative, catalase positive, nonmotile, pleomorphic coccobacillus. It is capable of growing within several different cell types, including macrophages, endothelial cells, and hepatocytes.[11, 12]

Tularemia is a zoonosis caused by the 2 species of F tularensis in the family Francisellaceae. Four subspecies of Francisella tularensis have been described, all of which have been associated with human disease, but only the F tularensis biovar tularensis ( Jellison Type A ) and F tularensis biovar holarctica (F tularensis biovar palaearctica or Jellison Type B) are common causes.

F tularensis biovar tularensis is found predominantly in North America, although cases have been described in Europe, and is an extremely virulent organism. As few as 10-50 organisms may result in disease if inhaled or injected intradermally, whereas oral ingestion would require as many as 108 organisms. F tularensis biovar holarctica is found primarily in Europe and Asia but has also been identified in cases of tularemia in North America. It is from this less virulent strain to humans and rabbits that the live virus vaccine strains are derived. F tularensis biovars novicida and mediasiatica are of low virulence. A Japanese F tularensis biovar holarctica variant japonica has been more recently characterized.

Traditionally, Francisella subspecies have been characterized on the basis of biochemical reactions, growth characteristics, and virulence properties; however, biochemical methods for differentiating between the subspecies have been found imprecise and newer molecular typing methodology has advanced classification of these organisms.

Tularemia is widely distributed; however, it is largely found in the northern hemisphere from 30-71° north latitude. Tularemia is most commonly described in the western and south central regions of the United States and in continental Europe and Asia. Transmission of tularemia to humans most often occurs through an insect bite or contact with contaminated animals or animal products during the processing of animal meat, skin and eating infected animals.[13] Thorough cooking is felt to lessen the likelihood of transmission.

Transmission has also been described via ingestion of or contact with contaminated water, exposure to contaminated mud, animal bites, and exposure to aerosolized water droplets or dust from contaminated soil or grains. Francisella has been shown to survive for prolonged periods of time in frozen water, mud or animal carcasses.[10] Carnivores, such as domestic cats, may transiently harbor Francisella in their mouths or on their claws after killing or feeding on infected prey, irrespective of whether they become infected. Human to human spread is not thought to occur. Cases have developed in laboratory workers, who should be notified in advance to safely handle specimens when tularemia is suspected.

F tularensis is capable of infecting hundreds of different invertebrate, aquatic, and terrestrial vertebrate species, including lagomorphs, rodents, ticks, mosquitos, and flies. In any geographic region, usually no more than a dozen mammals are important to its ecology; however, the overall ecology of F tularensis remains poorly characterized, particularly transmission cycles and specific differences between the 4 different subspecies.[14]

Lagomorphs, including Sylvilagus and Lepus species, have been historically recognized as common sources of transmission, hence the common names wild hare disease and rabbit skinners' disease. In North America, squirrels, muskrat, beavers, and voles have also been identified as natural reservoirs of organism. In the former Soviet Union, in addition to hares, hamsters, voles, water rats and mice have been shown to carry F tularensis. F tularensis live virus strain was demonstrated to infect amoebic cysts, multiply intracellularly in Acanthamoeba castellanii, and that co-culture of both leads to increased Francisella growth, which may provide natural aquatic reservoirs for the transmission of tularemia.

Bloodfeeding flies and arthropods are the most important vectors for tularemia in the United States. Biting flies, such as deerflies (Chrysops discalis), are the predominant vectors in the far western states, while ticks, primarily Amblyomma americanum, Dermacentor andersoni, and Dermacentor variabilis, are important vectors from the Rocky Mountains eastward. In Northern Europe and the former Soviet Union, mosquitos serve as the most important insect vector. Ticks serve as a particularly important reservoir and vector, as at least 13 different species have been found to be infected with F tularensis, and because vertical transmission of the organism transovarially has been demonstrated. The organism may be present in tick feces or saliva and can be inoculated directly or indirectly into the bite wound.

The cell wall of F tularensis possesses high levels of fatty acids and wild strains have an electron-transparent lipid-rich capsule. Loss of this capsule may result in loss of serum resistance and virulence; however, the capsule exhibits no innate immunogenicity or toxicity.

A subcutaneous inoculum of 10 organisms is sufficient to induce disease, whereas an inhalational exposure of 25 organisms may cause a severely debilitating or fatal disease. Over the first 3-5 days after cutaneous exposure, the organism multiplies locally and a papule forms. During the next 2-4 days, the site ulcerates. Organisms spread from the entry site to regional lymph nodes and may disseminate lympho-hematogenously to involve multiple organs. Patients are most likely bacteremic at this time, although it is not usually detected.

Infection produces an acute inflammatory response initially involving local macrophages, neutrophils, fibrin, and then T lymphocytes, epithelioid cells, and giant cells migrate into local necrotic tissue. As the area of necrosis expands, thrombosis of adjacent arteries and veins may occur. Granulomas develop, which may caseate and be mistaken for tuberculosis. Necrotic foci may coalesce to form abscesses. These changes occur in infected sites and have been demonstrated on autopsy in lymph nodes, liver, spleen, bone marrow, and the lungs.[15] Organisms may remain viable for prolonged periods of time.

During the second to third week of Francisella infection, humoral immunity develops against the organism's carbohydrate antigens. Agglutinating IgM, IgG, and IgA antibodies are seen at this time.[16, 12] Opsonizing IgG and IgM antibodies are also produced, which act in conjunction with complement (C3). B-cell deficient mice have been shown to have impaired clearance of organisms after primary infection with the less virulent vaccine strain of Francisella.[17]

Alpha/beta T-cell dependent immunity, involving either CD4+ or CD8+ T cells, and directed against protein antigens, has been demonstrated to be necessary for effective eradication of Francisella.[11, 12] Tularemia antigens, whether introduced by natural exposure or vaccination, have been shown to elicit a vigorous and long lasting TM response in humans. Some of these TM cells have lytic potential and they demonstrate the ability to enter both intestinal mucosal and nonmucosal lung sites.[18]

Preformed molecules on the surface of Francisella trigger rearrangements of the host cell cytoskeleton. Macrophage complement receptors interact with complement factor C3 fixed by molecules on the bacterial cell surface and bacteria are internalized by looping phagocytosis. Immediately after phagocytosis, the bacteria are housed in a nonacidified phagosome. Bacteria may degrade the phagosomal membrane and escape into the cytoplasm where they actively multiply. This can lead to cell death and liberation of bacteria. In rodent macrophages, bacterial survival has been shown to be associated with failure of phagosome-lysosome fusion, phagosome acidification, and utilization of host iron.[19]

Lack or minimal amounts of CD14 on human dendritic cells in the lung appears to contribute to F tularensis evasion of immune response.[20] Interferon gamma (IFN gamma) and TNF alpha activate macrophages to kill Francisella through the production of reactive nitrogen products such as nitric oxide (NO).[21] Neutrophils and mononuclear cells have been demonstrated to accumulate at infected liver foci and lyse Francisella -containing hepatocytes, releasing organisms from their relatively protected sequestered environment.[22] The ability of F tularensis to impair phagocyte function and survive in infected cells is central to its virulence. This intracellular life cycle has been shown to be related to the tightly regulated expression of a series of genes.[23, 24]

In the unique environment of the lung, oxygen-dependent neutrophil killing of wild virulent strains appears to be only partially effective.[25] Shortly after inhalation, Francisella are found inside cells that typically act as cytokine-producing first responders to infection, including airway macrophages and alveolar epithelial cells. Mouse experiments demonstrate lack of production of pro-inflammatory cytokines, including IL-12p40, TNF, IL-6, and IL-1 alpha. The exact mediators responsible for immunosuppression remain unclear; however, immunomodulatory factors such as TGF-beta and PGE-2 may be actively involved.

Interestingly, approximately 48-72 hours postinfection, a number of cytokines and chemokines, such as IFN-gamma and TNF, are upregulated and levels of proinflammatory mediators such as RANTES, IL-6, and IL-1 beta are detected. Unfortunately, the lung may contain more than 108 CFU bacteria and this upregulation may be too late to prevent death.[26, 11] This late "cytokine storm," similar to that demonstrated in other causes of severe bacterial sepsis, may actually prove harmful to the host, causing capillary leakage, tissue injury, and lethal organ failure.[27, 28]

The incubation period for tularemia depends on the size of the inoculum, but ranges from 1-21 days (average 2-6 d). Individuals with tularemia may be asymptomatic or acutely septic with rapid death. Six clinical forms of tularemia have been identified (see History). Each form is influenced by factors related to the host, organism, and route of transmission and host entry site.

Previous
Next

Epidemiology

Frequency

United States

Approximately 200 cases of tularemia are reported annually. In the United States, transmission had historically been most frequent from June through August and in December. The summer peak has been felt to be due to insect bites, while the winter peak has been attributed to hunting-associated cases. In more recent years, peak reporting has occurred in late spring and early summer.[8] From 1990-2000, 56% of cases reported in the United States were from Arkansas, Missouri, Oklahoma, and South Dakota, with high numbers of cases also reported in Massachusetts, Kansas, and Montana.[19] High incidence rates have been reported by indigenous Alaskans and Native Americans.[8]

Occupations and avocations associated with an increased risk of tularemia include laboratory work, veterinary practice, farming, landscaping, working with sheep, hunting and trapping, and meat handling.

International

Tularemia is found around the world, distributed within 30-71° northern latitude, but its incidence is unknown.

Mortality/Morbidity

Untreated, the mortality rate from tularemia is 5-30%, with the highest rate occurring with the typhoidal (systemic) form, particularly when accompanied by tularemia pneumonia. The mortality rate also depends on the strain involved; type A is significantly more virulent and is responsible for almost all reported deaths. The mortality rate is less than 1% with appropriate antibiotic therapy.

Race

No racial predilection is reported.

Sex

Male individuals are more frequently affected than female individuals, despite the lack of biologic affinity. This distribution primarily results from increased exposure to specific activities (eg, hunting and skinning animals) and increased occupational vulnerability among male individuals.

Age

Tularemia can be seen in individuals of any age; however, bimodal age peaks have been reported in the last decade, with incidence highest in those aged 5-9 years and those older than 75 years.[8]

Previous
 
 
Contributor Information and Disclosures
Author

Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM  Associate Professor, Education Officer, Department of Emergency Medicine, Hospital of the University of Pennsylvania; Director of Education and Research, PENN Travel Medicine

Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

William H Shoff, MD, DTM&H  Director, PENN Travel Medicine, Associate Professor, Department of Emergency Medicine, Hospital of the University of Pennsylvania

William H Shoff, MD, DTM&H is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Glaxo Smith Kline None None; Glaxo Smith Kline Honoraria Speaking and teaching

Specialty Editor Board

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Sanofi Pasteur Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Leslie L Barton, MD  Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

References
  1. Trevisanato SI. The 'Hittite plague', an epidemic of tularemia and the first record of biological warfare. Med Hypotheses. 2007;69(6):1371-4. [Medline].

  2. McCoy GW. A plague-like disease of rodents. Publ Hlth Bull. 1911;43:53-71.

  3. McCoy GW, Chapin CW. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent Bacterium tularense. J Infect Dis. 1912;10:61-72.

  4. Wherry WB, Lamb BH. Infection of man with Bacterium tularense. J Infect Dis. 1941;15:331-40.

  5. Jellison WL. Tularemia: Dr. Edward Francis and his first 23 isolates of Francisella tularensis. Bull Hist Med. Sep-Oct 1972;46(5):477-85. [Medline].

  6. Pohanka M, Skladal P. Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents - review. Folia Microbiol (Praha). 2009;54(4):263-72. [Medline].

  7. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. Jun 6 2001;285(21):2763-73. [Medline].

  8. Tularemia--United States, 1990-2000. MMWR Morb Mortal Wkly Rep. Mar 8 2002;51(9):181-4. [Medline].

  9. Feldman KA, Enscore RE, Lathrop SL, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med. Nov 29 2001;345(22):1601-6. [Medline].

  10. Reintjes R, Dedushaj I, Gjini A, et al. Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis. Jan 2002;8(1):69-73. [Medline]. [Full Text].

  11. Tarnvik A, Berglund L. Tularemia. Eur Respir J. 2003;21:361-73.

  12. Yee D, Rhinehart-Jones TR, Elkins KL. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol. Dec 1 1996;157(11):5042-8. [Medline].

  13. Hauri AM, Hofstetter I, Seibold E, Kaysser P, Eckert J, Neubauer H. Investigating an airborne tularemia outbreak, Germany. Emerg Infect Dis. Feb 2010;16(2):238-43. [Medline].

  14. Keim PS, Wagner DM. Humans and evolutionary and ecological forces shaped the phylogeography of recently emerged diseases. Nat Rev Microbiol. Nov 2009;7(11):813-21. [Medline]. [Full Text].

  15. Geyer SJ, Burkey A, Chandler FW. Tularemia. In: Connor DH. Pathology of Infectious Diseases. Stamford, CT: Appleton & Lange; 1997:869-73.

  16. Koskela P, Salminen A. Humoral immunity against Francisella tularensis after natural infection. J Clin Microbiol. Dec 1985;22(6):973-9. [Medline]. [Full Text].

  17. Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun. Nov 1999;67(11):6002-7. [Medline]. [Full Text].

  18. Salerno-Goncalves R, Hepburn MJ, Bavari S, Sztein MB. Generation of heterogeneous memory T cells by live attenuated tularemia vaccine in humans. Vaccine. 2010;28:195-206.

  19. Tularemia--Oklahoma, 2000. MMWR Morb Mortal Wkly Rep. Aug 24 2001;50(33):704-6. [Medline].

  20. Chase JC, Bosio CM. The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun. Jan 2010;78(1):154-67. [Medline].

  21. Green SJ, Nacy CA, Schreiber RD, et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun. Feb 1993;61(2):689-98. [Medline]. [Full Text].

  22. Conlan JW, North RJ. Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun. Dec 1992;60(12):5164-71. [Medline]. [Full Text].

  23. Meibom KL, Barel M, Charbit A. Loops and networks in control of Francisella tularensis virulence. Future Microbiol. Aug 2009;4:713-29. [Medline].

  24. Johansson A, Goransson I, Larsson P, Sjostedt A. Extensive allelic variation among Francisella tularensis strains in a short-sequence tandem repeat region. J Clin Microbiol. Sep 2001;39(9):3140-6. [Medline]. [Full Text].

  25. Conlan JW, KuoLee R, Shen H, Webb A. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog. Mar 2002;32(3):127-34. [Medline].

  26. Cowley SC. Editorial: Proinflammatory cytokines in pneumonic tularemia: too much too late?. J Leukoc Biol. Sep 2009;86(3):469-70. [Medline].

  27. Sharma J, Li Q, Mishra BB, Pena C, Teale JM. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J Leukoc Biol. Sep 2009;86(3):491-504. [Medline]. [Full Text].

  28. Washburn AM, Fullilove RE, Fullilove MT, et al. Acupuncture heroin detoxification: a single-blind clinical trial. J Subst Abuse Treat. Jul-Aug 1993;10(4):345-51. [Medline].

  29. Stoecker WV, Calcara DA, Malters JM, et al. Tick-borne febrile illnesss lacking specific symptoms. Missouri Med. 304-08;106.

  30. Hornick R. Tularemia revisited. N Engl J Med. Nov 29 2001;345(22):1637-9. [Medline].

  31. Fredricks DN, Remington JS. Tularemia presenting as community-acquired pneumonia. Implications in the era of managed care. Arch Intern Med. Oct 14 1996;156(18):2137-40. [Medline].

  32. Jensen WA, Kirsch CM. Tularemia. Semin Respir Infect. Sep 2003;18(3):146-58. [Medline].

  33. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore). Jul 1985;64(4):251-69. [Medline].

  34. Francis E. A summary of the present knowledge of Tularemia. Medicine. 1928;7:411-32.

  35. Svensson K, Granberg M, Karlsson L, Neubauerova V, Forsman M, Johansson A. A real-time PCR array for hierarchical identification of Francisella isolates. PLoS One. Dec 21 2009;4(12):e8360. [Medline]. [Full Text].

  36. Maurin M, Castan B, Roch N, Gestin B, Pelloux I, Mailles A. Real-time PCR for diagnosis of oculoglandular tularemia. Emerg Infect Dis. Jan 2010;16(1):152-3. [Medline].

  37. Johansson A, Berglund L, Eriksson U, et al. Comparative analysis of PCR versus culture for diagnosis of ulceroglandular tularemia. J Clin Microbiol. 2003;38:22-26.

  38. Finnish Medical Society Duodecim. Tularaemia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons;. Apr 27 2008:[Full Text].

  39. Enderlin G, Morales L, Jacobs RF, Cross JT. Steptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 2004;19:42-7.

  40. Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis. Dec 1993;17(6):976-80. [Medline].

  41. Oyston PC. Francisella tularensis vaccines. Vaccine. Nov 5 2009;27 Suppl 4:D48-51. [Medline].

  42. Pierce JR Jr, Gerald TS, West TA, Alexander JL, Bell TE, Duke D. Tularemia outbreak at a metropolitan airport, Texas. Biosecur Bioterror. Sep 2009;7(3):331-6. [Medline].

  43. Pechous RD, McCarthy TR, Zahrt TC. Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev. Dec 2009;73(4):684-711. [Medline]. [Full Text].

  44. Akalin H, Helvaci S, Gedikoglu S. Re-emergence of tularemia in Turkey. Int J Infect Dis. Sep 2009;13(5):547-51. [Medline].

  45. Atmaca S, Bayraktar C, Cengel S, Koyuncu M. Tularemia is becoming increasingly important as a differential diagnosis in suspicious neck masses: experience in Turkey. Eur Arch Otorhinolaryngol. Oct 2009;266(10):1595-8. [Medline].

  46. Barut S, Cetin I. A tularemia outbreak in an extended family in Tokat Province, Turkey: observing the attack rate of tularemia. Int J Infect Dis. Nov 2009;13(6):745-8. [Medline].

  47. Bolgiano EB, Sexton J. Tick-borne illnesses. In: Rosen P, ed. Emergency Medicine: Concepts and Clinical Practice. Vol 3. 4th ed. St Louis, Mo: Mosby; 1998:2612-4.

  48. Bratton RL, Corey R. Tick-borne disease. Am Fam Physician. Jun 15 2005;71(12):2323-30. [Medline].

  49. Cronquist SD. Tularemia: the disease and the weapon. Dermatol Clin. Jul 2004;22(3):313-20, vi-vii. [Medline].

  50. Daya M, Nakamura Y. Pulmonary disease from biological agents: anthrax, plague, Q fever, and tularemia. Crit Care Clin. Oct 2005;21(4):747-63, vii. [Medline].

  51. Dixon B. A hidden danger. Lancet Infect Dis. Aug 2009;9(8):463. [Medline].

  52. England K, am Ende C, Lu H, et al. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. J Antimicrob Chemother. Nov 2009;64(5):1052-61. [Medline]. [Full Text].

  53. Faul JL, Doyle RL, Kao PN, Ruoss SJ. Tick-borne pulmonary disease: update on diagnosis and management. Chest. Jul 1999;116(1):222-30. [Medline].

  54. Fortier AH, Leiby DA, Narayanan RB, et al. Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun. Apr 1995;63(4):1478-83. [Medline]. [Full Text].

  55. Greenberg SB. Serious waterborne and wilderness infections. Crit Care Clin. Apr 1999;15(2):387-414. [Medline].

  56. Grunow R, Splettstoesser W, McDonald S, et al. Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR. Clin Diagn Lab Immunol. Jan 2000;7(1):86-90. [Medline]. [Full Text].

  57. Johansson A, Berglund L, Gothefors L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J. May 2000;19(5):449-53. [Medline].

  58. Labayru C, Palop A, Lopez-Urrutia L, et al. [Francisella tularensis: update on microbiological diagnosis after an epidemic outbreak]. Enferm Infecc Microbiol Clin. Nov 1999;17(9):458-62. [Medline].

  59. Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis. Oct 1999;29(4):922-4. [Medline].

  60. Markowitz LE, Hynes NA, de la Cruz P, et al. Tick-borne tularemia. An outbreak of lymphadenopathy in children. JAMA. Nov 22-29 1985;254(20):2922-5. [Medline].

  61. Osterbauer PJ, Dobbs MR. Neurobiological weapons. Neurol Clin. May 2005;23(2):599-621. [Medline].

  62. Price KM, Woodward JA. Management of tick infestation of the eyelid. Ophthal Plast Reconstr Surg. Jul-Aug 2009;25(4):328-30. [Medline].

  63. Schuster GS. Bacterial and protozoal infections. Infect Dis Clin North Am. Dec 1999;13(4):797-816. [Medline].

  64. Senol M, Ozcan A, Karincaoglu Y, Aydin A, Ozerol IH. Tularemia: a case transmitted from a sheep. Cutis. Jan 1999;63(1):49-51. [Medline].

  65. Smego RA Jr, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore). Jan 1999;78(1):38-63. [Medline].

  66. Tularemia: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis. CIDRAP [serial online]. 04/02/2009;Accessed 02/05/2010. Available at http://www.cidrap.umn.edu/idsa/bt/tularemia/biofacts/tularemiafactsheet.html.

  67. Weber DJ, Isbey S. Tick-borne diseases. In: Emergency Medicine: A Comprehensive Study Guide. 4th ed. New York, NY: McGraw-Hill; 1996:729-30.

Previous
Next
 
Ulceroglandular tularemia on the face. Courtesy of Dr Hon Pak.
Ulceroglandular tularemia on an extremity. Courtesy of Dr Hon Pak.
Ulceroglandular type of tularemia on the hand. Courtesy of Dr Hon Pak.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.